Pure (-)-epicatechin and high-flavanol milk chocolate improves flow-mediated dilatation in healthy men: a clinical trial-based investigation

[thumbnail of 15017254_Castle_form.pdf]
Text - Thesis Deposit Form
· Restricted to Repository staff only
Restricted to Repository staff only

Please see our End User Agreement.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email

Castle, S. M. (2017) Pure (-)-epicatechin and high-flavanol milk chocolate improves flow-mediated dilatation in healthy men: a clinical trial-based investigation. PhD thesis, University of Reading.

Abstract/Summary

Background: Strong evidence supports the vasoactivity of cocoa flavanols, particularly (-)-epicatechin (EC). However, full dose-dependency of EC remains unclear, emphasising the need for further research and clinical trials to inform public health and future dietary recommendations. Objective: To conduct a clinical trial-based investigation in healthy men to elucidate dose-dependent vascular effects, primarily assessing FMD at doses ≤ 1 mg/kg BW of pure compound over an acute timeframe (6 h), and secondly, assessing bidaily intake of high-flavanol milk chocolate (HFMC) over 2 weeks for a longer-term insight of dietary flavanol intake. Design: Two randomised, controlled, double-blind intervention trials were conducted in 20 and 33 healthy men (18-40 y). Acute study subjects crossed over 4 treatment arms (control 0.0, 0.1, 0.5, and 1 mg/kg BW pure EC) and plasma samples and vascular measures were taken at baseline, 1, 2, 4 and 6 h post-treatment. Acute-on-chronic study subjects followed bidaily intake of either HFMC (35 mg EC/d) or LFMC (0 mg EC/d) over 2 weeks. Plasma samples and FMD measures were taken at the first (day 0) and last day of intervention (day 14), and post-intervention (≥ day 28). Acute measures (2 h) were also assessed at day 0 and day 14. Results: In the acute study we observed significant improvements in FMD% (>1.2%) after ingestion of doses 0.5 and 1 mg/kg BW at 2 h post-ingestion (P <0.01-0.001). Results of the acute-on-chronic study demonstrated significant improvements in FMD% within the HFMC group; I) acutely (2 h) at day 0 (0.7 %; P<O.OI); 2) chronically at day 14 (1.0%;P<O.OOI), and 3) a sustained increase in FMD post-intervention (0.9%; P<O.OOI). EC metabolites were able to predict changes in both trials, although, no other vascular or haematological markers were changed significantly. Conclusion: We show for t,le first time 0.5 mg/kg BW of pure EC can significantly induce acute improvements in FMD. We also conclude that long-term (>2 weeks) bidaily intake of HFMC results in sustained improvements in FMD. Both studies demonstrated clinically relevant increased in FMD. Our data supports the vasoactivity, linking to cardioprotection, of EC, and stereoisomer-specific foods, by demonstrating enhanced vascular function in a 'low-risk' population.

Item Type Thesis (PhD)
URI https://reading-clone.eprints-hosting.org/id/eprint/73500
Divisions Life Sciences > School of Chemistry, Food and Pharmacy > Department of Food and Nutritional Sciences
Date on Title Page 2016
Download/View statistics View download statistics for this item

University Staff: Request a correction | Centaur Editors: Update this record

Search Google Scholar